In Brief DNA methyltransferase inhibitors upregulate endogenous retroviruses in tumor cells to induce an growth-inhibiting immune response. High expression of the genes associated with the anti-viral response seems to potentiate a response to immune checkpoint therapy.
SUMMARY
We show that DNA methyltransferase inhibitors (DNMTis) upregulate immune signaling in cancer through the viral defense pathway. In ovarian cancer (OC), DNMTis trigger cytosolic sensing of doublestranded RNA (dsRNA) causing a type I interferon response and apoptosis. Knocking down dsRNA sensors TLR3 and MAVS reduces this response 2-fold and blocking interferon beta or its receptor abrogates it. Upregulation of hypermethylated endogenous retrovirus (ERV) genes accompanies the response and ERV overexpression activates the response. Basal levels of ERV and viral defense gene expression significantly correlate in primary OC and the latter signature separates primary samples for multiple tumor types from The Cancer Genome Atlas into low versus high expression groups. In melanoma patients treated with an immune checkpoint therapy, high viral defense signature expression in tumors significantly associates with durable clinical response and DNMTi treatment sensitizes to anti-CTLA4 therapy in a preclinical melanoma model.
INTRODUCTION
DNA methyltransferase inhibitors (DNMTis) such as 5-azacytidine (Aza) and 5-aza-2 0 -deoxycytidine (Dac) are effective cancer therapies in hematologic neoplasms (Issa, 2005; Matei et al., 2012) and are Food and Drug Administration (FDA)-approved for the pre-leukemic disorder myelodysplasia (MDS) (Kaminskas et al., 2005) . These cytidine analogs incorporate into DNA, block catalytic actions of DNA methyltransferases (DNMTs), and trigger their degradation (Stresemann et al., 2006) . Preclinically, low doses avoid early cytotoxicity and DNA damage, allowing cells to exhibit apparent reprogramming and blunting of tumorigenicity (Tsai et al., 2012) . Mechanisms can include reversal of abnormal promoter DNA methylation, re-expression of silenced genes including tumor suppressors (Baylin and Jones, 2011) , and changes to cancer signaling pathways including apoptosis, cell-cycle activity, and stem cell functions (Tsai et al., 2012) .
A long recognized activity of DNMTis described by others (Karpf et al., 1999 (Karpf et al., , 2004 and our group (Li et al., 2014; Wrangle et al., 2013) , is induction of immune responses in cancer cells. In recent clinical trials for non-small cell lung cancer (NSCLC) (Juergens et al., 2011; Wrangle et al., 2013) a small number of patients had remarkably robust and durable responses to immune checkpoint blockade therapy after first receiving Aza (Wrangle et al., 2013) . This immune therapy alone also has activity against NSCLC (Brahmer et al., 2010 Topalian et al., 2012) . A larger trial is now ongoing to determine if Aza can indeed prime patients for sensitization to checkpoint inhibition (Brahmer, 2015) . For NSCLC and other tumor types, Aza induces interferon signaling and concordant upregulation of surface antigens and their assembly proteins, viral defense pathways, and transcript and surface protein levels of PD-L1, the key checkpoint ligand targeted in the above immunotherapy (Li et al., 2014; Wrangle et al., 2013) . Indeed, we have defined a 300-gene expression signature we termed Aza-induced immune genes or AIM (Li et al., 2014) for which activation is greatest for epithelial ovarian cancer (EOC) and NSCLC (Li et al., 2014) . Genome-wide expression of AIM separates primary EOC, NSCLC, and other cancers into high and low expression groups (Li et al., 2014) . We hypothesize the low group may represent an ''immune evasion/immune editing'' pattern (Drake et al., 2006; Schreiber et al., 2011) that Aza could reverse to sensitize patients to subsequent immune therapy (Li et al., 2014) .
We now show that a major mechanism underlying the Aza-triggered immune response is induction of a cytosolic double-stranded RNA (dsRNA) sensing pathway used by epithelial and other cell types as a viral defense mechanism that triggers a type I interferon response (Kulaeva et al., 2003; Sistigu et al., 2014) . A key contributor is induction of increased expression of multiple DNA hypermethylated endogenous retroviruses (ERVs). In The Cancer Genome Atlas (TCGA), the viral defense gene expression separates primary EOC and other cancers into high and low expression and high tumor expression strongly associates with clinical benefit in a trial of immune checkpoint therapy for advanced melanoma. Aza sensitizes to immune checkpoint blockade in a pre-clinical model of melanoma. We thus define a potential approach in which an epigenetic therapy may sensitize cancer cells to various immunotherapies.
RESULTS
DNMTis Trigger Viral Defense and Type I Interferon Signaling Induction of AIM in a previous study of 23 EOC cell lines (Li et al., 2014) included, in addition to previously reported DNA hypermethylated cancer testis antigens (MAGEA4, MAGEA9, NY-ESO-1) (James et al., 2013; Karpf et al., 2004 Karpf et al., , 2009 Odunsi et al., 2014) , interferon/viral defense, antigen processing and presentation, and host immune cell attraction genes ( Figure 1A ). Direct Aza targeting of DNMTs for these changes is suggested by similar findings in DKO colon cancer cells genetically disrupted for two major DNMTs (DNMT1
) versus parental, wild-type HCT116 cells ( Figure 1A ). The induced responses may not be a general stress phenomenon as they did not occur with carboplatin, a cytotoxic agent commonly used in EOC treatment ( Figure 1B ). Aza and Dac incorporate into DNA, inhibiting three DNA methyltransferases, but Aza also incorporates into RNA, inhibiting the RNA methyltransferase DNMT2 (Schaefer et al., 2009 ). Aza thus can demethylate RNA, and unmethylated RNA may activate TLR3 and the interferon response (Karikó et al., 2005) . However, Dac and Aza both mimicked the DKO cell line results ( Figures 1A, 1C, 1D , S1A, and S1B) strongly suggesting that the drugs directly target DNA methylation to trigger the interferon response.
Aza and Dac similarly triggered an interferon response that includes interferon beta (IFNb1) and a panel of interferon-stimulated genes (ISGs) (IFI16, IFI27, IFI44, IFI44L, MX1, and OASL) ( Figures 1C, 1D , S1A, and S1B). Each ISG functions predominantly in anti-viral and anti-proliferative signaling ( Figure 2A ; Ivashkiv and Donlin, 2014) . In four EOC cell lines, key upstream genes in the type I Interferon pathway (IFNb1, IRF7, and STAT1) were generally upregulated at the fourth day following the end of Aza treatment (''day 7'') and further increased by day 10 ( Figures 1C, 1D , S1A, and S1B). Importantly, cytosolic sensors for DNA (MB21D1/CGAS and TMEM173/STING) and RNA (DDX41, DDX58/RIG-I, and IFIH1/MDA5) were also variably upregulated ( Figures 1A, 1C, 1D , S1A, and S1B). In A2780 and TykNu, but not Hey or Kuramochi, cell lines, variable increases occurred in type III interferon signaling genes, also involved in response to viruses . These included IFNL1 (IL28A) and IFNL3 (IL29) ligands ( Figure S1C ) and especially the IFN III receptor IFNLR1 ( Figure S1C ), known to be methylated and activated by epigenetic therapy .
Key viral RNA sensing proteins include TLR3 on the endosomal membrane and MDA5, PKR, and RIG-I in the cytoplasm (Figure 2A ). These induce IRF3, IRF7, and NF-kB to translocate to the nucleus and activate transcription of IFNb1 (Ivashkiv and Donlin, 2014) . IRF7 is frequently promoter DNA hypermethylated in cancer and the associated low basal expression can be reversed by Aza in squamous NSCLC (Wrangle et al., 2013) . Among 23 EOC lines examined, IRF7 was hypermethylated in only one, A2780 (Li et al., 2014) (Figure S3A) Figure S1 . Domcke et al., 2013) . Aza induced partial IRF7 demethylation and increased expression in this cell line at days 7 and 10 while carboplatin did not ( Figures 1B, 1C , and S3A), and IRF7 knockdown significantly reduced the Aza interferon response ( Figures S3B and S3C ). Such IRF7 induction did not occur in two EOC lines or the HCT116 colon cancer cell line where the gene is not hypermethylated ( Figures 1D, S1A , S1B, and S3A). When IRF7 is not silenced, other mechanisms must then be operative for Aza to trigger viral defense signaling. Secreted IFNb is critical to this signaling and, through interaction with surface receptors IFNAR1/2, activates JAK/STAT signaling, transcription of ISGs, and resultant translation inhibition and apoptosis (Platanias, 2005; Ivashkiv and Donlin, 2014) (Figure 2A) . Indeed, media transferred to untreated cells from Azatreated cells 7 days after drug withdrawal caused an interferon response with increased expression of ISGs IFI27, IFI44, and IFI44L ( Figure 2B ). Moreover, Aza treatment induced secreted IFNb in media (Figures 2C and S2A) and an IFNb blocking antibody significantly blocked the Aza-induced ISG media response ( Figure 2B ). Like type I IFN signaling, type III IFN signaling can be activated by viral infection (Robek et al., 2005; . However, even though we observed upregulation of type III ligand transcripts IFNL1 (IL28A) and IFNL3 (IL29) ( Figure S1C ), secreted type III interferon proteins were undetectable by ELISA ( Figure S2B ).
Aza appears to activate type I, IFNb-mediated signaling through JAK/STAT, as the JAK/STAT inhibitor ruxolitinib strongly reduced ISG responses ( Figures 2D and S2C ). Further, antibody blocking of IFNAR2, the IFNb receptor, abrogated Aza induction of IFI27, IFI44L, and IFI6 transcription ( Figures 3A and S2D ), as did inhibition of IFNb itself (Figures 3B and S2E) . In contrast, blocking the type III interferon, IL10RB receptor, gave only a modest block of IFI27 increase ( Figure S2F ). IFNb binding to IFNAR2 also may contribute to late, Aza-induced apoptosis that peaks at 4-7 days after Aza withdrawal, since anti-IFNAR2 led to a lower ratio of cleaved/total PARP (Figures 3A, 3C, and S2D and S2G).
DNMTis Trigger Viral Defense through Induction of dsRNA Aza-induced viral defense genes and IFNb1 are not generally DNA methylated at promoter regions (Li et al., 2014) , thus Aza may activate the pathway upstream of these genes. We considered increases in dsRNA, viral single-stranded RNA (ssRNA), and unmethylated CpG DNA that might trigger cytosolic sensors (Sun et al., 2013) . Indeed, 3 days after ending Aza treatment of A2780 and TykNu ovarian cancer cells and subsequent transfection into HT29 colon cancer cells, known to have a robust interferon response (Chiappinelli et al., 2012) , cytoplasmic total RNA (without rRNA) and PolyA + RNA, but not PolyA À RNA or DNA, increased IFNb1 transcripts ( Figure 3D ) and downstream ISGs ( Figures 3E and S3D ). Further, RNaseIII treatment of the cytosolic nucleic acids, which specifically digests dsRNA, eliminated the IFNb1 upregulation ( Figure 4A ), but this was not seen with RNaseH treatment that digests DNA-RNA hybrids ( Figure S4A ). If dsRNA is required for the above Aza effects, then the key cytosolic sensors, TLR3, MDA5 (IFIH1), and RIG-I (DDX58), the latter two signaling through the mitochondrial protein, MAVS, should be involved in subsequent IFNb1 induction ( Figure 2A ). Aza increased transcript ( Figure 1A ) and protein levels for these ( Figure 4B ). However, RIG-I, which requires a 5 0 triphosphate group on RNA for activation, is likely not a key player since alkaline phosphatase treatment of cytosolic nucleic acid fractions did not abolish IFNb1 upregulation ( Figure S4D ). In contrast, knockdown of TLR3 and MAVS in A2780 cells (Figure 2A ) decreased Aza upregulation of interferon genes IFNB1, IFI44, IFI44L, and IFI27 by 2-fold as did MAVS knockdown ( Figures  4C, 4D , and S4B). In TykNu, knockdown of TLR3 and MAVS significantly blunted Aza induction of these gene responses ( Figure S4C ). Importantly, knock down of STING, the cytosolic DNA sensor (Mankan et al., 2014) did not blunt Aza-induced interferon signaling ( Figures 4C and 4D ). A previous report had implicated STING in viral cytosolic sensing in B cells, but this was dependent upon viral reverse transcriptase activity, likely to be low in our cells (Mankan et al., 2014) . We thus conclude that MAVS and TLR3 are centrally involved in Aza triggering cytosolic sensors to induce an interferon response.
Aza-Induced Human Endogenous Retrovirus Transcripts Can Activate Viral Defense Responses in EOC
The above data suggests Aza might activate endogenous retroviral sequences (ERVs) that constitute more than 8% of the human genome, can activate cytosolic RNA sensors, and are silenced in normal somatic cells by promoter DNA methylation (Bannert and Kurth, 2004; Tristem, 2000; Hurst and Magiorkinis, 2014; Mankan et al., 2014) . Some cancers lose ERV DNA methylation and aberrantly overexpress ERVs (Larsen et al., 2009; Rycaj et al., 2015; Strick et al., 2007; Strissel et al., 2012; Wang-Johanning et al., 2001 while others maintain silencing. Aza can induce specific ERV transcripts in melanoma, choriocarcinoma, and endometrial cancer cells (Laska et al., 2013; Ruebner et al., 2013; Stengel et al., 2010; Strissel et al., 2012) . Indeed, in initial testing, the ERVK subfamily (WangJohanning et al., 2003) transcripts increased 2.5-fold in the A2780 cell line upon Aza treatment (data not shown). Upregulation of individual ERVs (22 full-length env, 6 partial coding env, 1 full-length gag, and 2 partial coding pols) (Tables S1 and S2 Figure S6A ). Further linking ERVs with a dsRNA-triggered IFN response, bidirectional transcription producing sense and anti-sense transcripts occurred for Syncytin-1 and five env-Fc2 gene loci, but not b-actin, in three EOC lines and HCT 116 and DKO cells (Figure 5C ; Table S2 ), analyzed by the TAG-aided sense/antisense transcript detection (TASA-TD) technique (Henke et al., 2015) . Such sense and antisense transcripts can form dsRNA (Faghihi et al., 2008; Su et al., 2012) . Interestingly for TykNu, there was a 6.69-fold increase of env-Fc2 antisense transcript levels compared to the sense transcript ( Figure 5C ) but substantially lower antisense transcripts were seen in both HCT116 and DKO cells (Figures 5C and 6A) . Disrupting DNMTs seems integral to the above ERV upregulation since increases of env-Fc2 and erv9-1 occurred in DKO versus wild-type HCT116 cells ( Figure 6A ).
ERV transcripts seem directly involved in the Aza responses that, first, although drug-induced upregulation of ERV transcripts began early after Aza, both ERVs and viral defense gene increases generally peaked by day 7 (Figures S6D and S6J) . Second, ERV env proteins such as Syn1 and ERV-3 were not increased after Aza treatment, supporting a dominant role for viral defense signaling via RNA transcripts ( Figures 6D, S6B , and S6C). Third, overexpression of ERV-3, EnvW2, and Syncytin-1 in TykNu ( Figures 6E and 6J ), A2780 ( Figure S6D) , and Hey cells ( Figures S6E and S6J) , as compared to control genes, increased the same interferon genes induced by Aza (IFNb1, Figures 3D and 3E . IFNb1 transcripts were measured at 24 hr. y axis = IFNB1 fold change, *p % 0.05 for fold change over untreated;^p % 0.05 for Mock or Aza + versus À RNaseIII. (B) Western blots for MDA5, RIG-I, and TLR3 in A2780 cells at four (day 7) and seven (day 10) days after Mock versus 500 nM Aza (Aza) for 3 days. The same A2780 lysate gel was blotted for MDA5 and b-actin, then stripped and reprobed for RIG-I and TLR3. The space between the MDA5, RIG-I, and TLR3 and b-actin proteins was cropped out to conserve space. (C) Knockdown upon lentiviral infection, with puromycin selection, of A2780 and TykNu with shGFP, shTLR3, and shSTING hairpins. Immunoblotting with anti-TLR3, anti-STING, and anti-b-actin. Densitometry fold change, normalized to mock or shGFP, shown at the bottom of the gels. The shTLR3 and shSTING cell lysates were run on two separate gels to perform western blots. The space in between the TLR3 and b-actin proteins was cropped out to conserve space. The STING western blot was stripped and reprobed with b-actin as a loading control. (D) qRT-PCR for ISGs from (B) and (C). *p % 0.05 Aza over Mock;^p % 0.05 shGFP versus each shRNA sensor with mean fold change ± SEM of three biological replicates. See also Figure S4 .
IFI27, and IFI44L).
The increases often exceeded that for the drug likely because total ERV RNA molecules were higher in the overexpression experiments ( Figures S6F-S6I) . Finally, although siRNA knockdown of individual ERVs (Syncytin-1, ERV-3) during Aza treatment produced more complex results, targeting two ERVs significantly blunted the Aza-induced gene expression of IFI27, IFI44L, and IFI6 in TykNu cells, but not A2780 or Hey cells ( Figure S7A ).
Importantly, a driving role for ERV transcripts in triggering Aza-induced viral defense gene responses is evidenced by a high correlation of basal levels of both in 19 primary EOC. Total molecules of 22 ERV env genes queried were increased (p < 0.05) in tumor versus normal (n = 9) and divided tumors into lower (n = 9) and higher ERV (n = 10) expression groups as compared to normal controls. High ERV tumors had significantly higher viral defense response gene expression (p = 0.000141) ( Figure 7A ).
Viral Defense Gene Levels Divide Human Tumors into High and Low Expression Groups that Track with Responses to Immune Checkpoint Therapy
Human cancers can evolve immune evasion to become less responsive to immune modulation (Drake et al., 2006; Schreiber et al., 2011) . In this regard, basal transcript levels for the Azainduced viral defense genes grouped primary EOC, breast, colon, and lung cancers, and melanoma from The Cancer Genome Atlas (TCGA) studies into high and low groups ( Figures 7B and S7C-S7F ). For EOC, this basal expression divided tumors into high, medium, and low expression groups and the former two encompass virtually all of the TCGA (Verhaak et al., 2013) immune reactive (IMR) good prognosis tumors. The Low group encompasses the PRO (high proliferative), poor prognosis subtype (p < 0.001 to 0.0001) (Figures 7B and S7B) . Interestingly, virtually all of the right-sided colon cancers with a high DNA hypermethylation frequency phenotype (p < 0.002), termed CIMP, which have a high A B C Figure 5 . Aza Upregulates Sense and Antisense ERV Transcripts RNA was isolated from cells at last (day 3), one (day 4), three (day 7), and seven (day 10) days after Mock or 500 nM Aza (Aza) for 3 days. (A) Total number of molecules for all ERV genes (y axis = ERV molecules/ng RNA). Error bars, SEM for four independent experiments; numbers above bars, significant data for indicated days; gray, Mock; black, Aza. (B) qRT-PCR of ERV genes in A2780 cells for four independent experiments. y axis, fold increases for Aza/Mock ± SEM and normalized to Mock = 1. White bars, non-significant; colored bars, significant ERV gene induction (p < 0.05). (C) TASA-TD PCR amplified sense and antisense transcripts of the env-Fc2 (731 bp) and Syncytin-1 (202 bp) genes from first strand cDNA. Aza-treated A2780, Hey, and TykNu, and HCT116 and DKO cells are indicated. Ratios of sense (s) and antisense (as) determined by ImageJ. PCR primers, gene-specific (GS); TAG. b-actin sense 399 bp amplification product = negative control for as transcripts (Chen et al., 2004) . The products from TASA-TD PCR were run on the same gel, then cropped and presented. See also Figure S5. burden of DNA mutations and respond robustly to immune checkpoint therapy (Le et al., 2015) , were in the High and Intermediate groups ( Figure S7C ). High mutation burden has recently been defined as a key correlate to response to immune checkpoint therapy (Rizvi et al., 2015; Snyder et al., 2014) . Similar sharp high versus low clustering is seen for subgroups of breast and lung cancers and melanoma (Guan et al., 2015) (Figures S7D-S7F ), the last being very responsive to immune checkpoint therapy (Topalian et al., 2015; Hodi et al., 2010; Weber et al., 2015) .
Could the levels of viral defense pathway signaling correlate with improved responses to immune checkpoint therapy? Indeed, for RNA-seq transcriptomes of melanoma patients treated with anti-CTLA-4, high levels of the viral defense signature expression in tumor samples correlated with long term benefit (disease control [stable disease or better] >6 months as measured radiographically) in patients treated with anti-CTLA-4 therapy (Snyder et al., 2014) (Figures 7C and 7D ; Tables  S5 and S6 ). Importantly, high viral defense signature again correlated with high mutational burden ( Figure 7C 
DISCUSSION
Our present data now provide functional context for our earlier reports that DNMTis induce a complex set of immune pathway responses in tumor cells (Li et al., 2014; Wrangle et al., 2013) . DNMTis trigger cytoplasmic dsRNA sensing, central to cellular viral defense responses, and activate interferon in EOC and colon cancer cells by disrupting DNMTs. This activation could induce tumor attraction of lymphocytes (Ivashkiv and Donlin, 2014) . There are some important implications for one of the most exciting new developments in cancer treatment, immune checkpoint therapy (Brahmer et al., 2010 Berger et al., 2008; Leach et al., 1996; Topalian et al., 2015; Hodi et al., 2010; Weber et al., 2015) and for underlying mechanisms inherent to both tumor and host cells for reversal of immune tolerance in tumor infiltrating T-lymphocytes (Pardoll, 2012) . (A) Heatmap comparing basal levels of viral defense genes and ERVs in primary EOC. The cut-off for lower or higher ERVs was the mean control tissue value of 237.57 ± 83.05 molecules/ng RNA. Mean ISGs of the high ERV ovarian tumor (T) cohort (n = 10) is 12.65-fold higher than the mean of ISGs of the low ERV cohort (n = 9). The (*) denotes that eight of ten high ERV tumors had significantly higher ISG expression compared to the low ERV tumors. ISG expression is organized according to low and high ERV expression cohorts in arbitrary units; color code from blue to red shows increasing ISG expression. For clusters (k = 6), differences are significant between the high ERV expression (2.5 ± 0.37) and the low ERV expression cohort (5.33 ± 0.28).
(B) Interferon-stimulated viral defense genes upregulated at least 2-fold by Aza in EOC cell lines (right y axis) were used to cluster EOC tumors for RNA-seq data (blue, low; red, high) from The Cancer Genome Atlas (TCGA). EOC TCGA subtypes are shown: DIF (differentiated), IMR (immune reactive), MES (mesenchymal), and PRO (proliferative).
(C and D) Viral defense gene signature is upregulated in tumors from anti-CTLA-4-treated metastatic melanoma patients who derived durable clinical benefit (complete response, partial response, or progression free-survival >6 months as previously described) (Snyder et al., 2014) See also Figure S7 and Tables S5 and S6 .
Indeed, basal levels of our viral defense gene transcripts divide EOC, and other major cancer types in TCGA, into low and high expression subgroups. Perhaps most intriguingly, such high basal expression in tumors tracks with favorable patient responses in a trial of immune checkpoint therapy for advanced melanoma, and strong Aza sensitization to immune checkpoint therapy is seen in a pre-clinical mouse melanoma model. A major trigger of the Aza-induced viral defense response appears to be bidirectional transcription of ERVs that are known to fold into dsRNA secondary structures. ERVs, representing more than 8% of the human genome (Bannert and Kurth, 2004; Tristem, 2000) , integrated into the genome of mammals between 0.1 and 40 million years ago via exogenous retroviral infections of germ cells (Egan et al., 2004; Turner et al., 2001) . Most ERV genes are non-functional due to DNA recombination, mutations, and deletions, but some produce functional proteins including group-specific antigen (gag), polymerase (pol) with reverse transcriptase (RT), and the envelope (env) surface unit (SU) with a transmembrane immunosuppressive-like peptide (Mi et al., 2000; Blaise et al., 2005; de Parseval et al., 2003; Villesen et al., 2004) . The env gene of ERVW-1 (chromosome 7q21.2) called Syncytin-1 has an essential role in placentogenesis (Blond et al., 1999; Mi et al., 2000) .
Importantly, and key to our findings, a major function of DNA methylation in humans is silencing of ERVs and other viral sequences in the human genome; up to 90% of methylated CpGs are located in 45% of the human genome harboring repetitive elements like ERVs (Walsh et al., 1998; Bestor and Tycko, 1996) . However, ERV genes are unmethylated and expressed in embryonic stem cells (Santoni et al., 2012) and especially Syncytin-1 is epigenetically regulated throughout placentogenesis (Matousková et al., 2006) . Some tumors have ERV demethylation and increased expression such as the ERV-K (HML-2) 5 0 LTR-UTR in melanoma (Stengel et al., 2010 ) and the 5 0 -LTR region of several ERVs in testicular cancer (Gimenez et al., 2010) . A 20% overall mean demethylation of single CpGs in the ERVW-1 5 0 LTR regulating Syncytin-1 correlates with increased expression in endometrial cancer (Strissel et al., 2012) . Indeed, ERVs can be targeted as tumor-associated antigens on melanoma cells (Cooper et al., 2015) . In contrast, as in our present data and those of others (Maksakova et al., 2008) , in some cancers, individual ERVs can maintain full or partial promoter DNA methylation and low expression and DNMTis can induce ERV demethylation and viral defense signaling in human embryonic stem cells (Grow et al., 2015) .
In addition to ERVs, other noncoding RNAs could contribute to the Aza-induced immune response, such as repetitive Alu elements (Tarallo et al., 2012) . UV light can damage small nucleolar RNA and activate an interferon response via TLR3 (Bernard et al., 2012) and very high dose (10 mM) Dac can induce an interferon response, apoptosis, increased ERVs and repetitive satellite RNAs in p53 null mouse fibroblasts (Leonova et al., 2013) . We suspect, however, that such high Dac doses induce DNA damage rather than simply epigenetic effects. Half of the ovarian cancer lines we studied (Li et al., 2014) have wild-type P53 but we see no differences in Aza interferon response between these and those with mutant P53.
The high translational connotations of our findings, including the small number of patients in clinical trials for NSCLC who may have been sensitized by epigenetic priming to immune therapy (Wrangle et al., 2013) , remain to be validated in larger clinical trials. These are ongoing for NSCLC (Brahmer, 2015) and planned for advanced ovarian cancer. Moreover, ERV-K env proteins have been shown to increase immunotherapeutic potential of melanoma, breast, and ovarian cancer patients (Rycaj et al., 2015; Wang-Johanning et al., 2012; Cooper et al., 2015) . Also, our hypotheses that drugs like Aza might sensitize patients with multiple cancer types to immune checkpoint blockade and other immunotherapies are further strengthened by the data in our pre-clinical melanoma model. For immune checkpoint therapy, in addition to the functional significance of our data, a potential biomarker strategy is suggested by our findings in a melanoma trial. The high correlation of viral defense signaling with mutational burden suggests that genetic changes, increases in ERVs, and viral defense genes could predict response to immune checkpoint and other immunomodulatory approaches. Finally, our drug approach to upregulate viral defense signaling might be compared to the use of oncolytic viruses to induce inflammatory immune infiltrates at tumor sites to sensitize to immunomodulation (Zamarin et al., 2014) .
EXPERIMENTAL PROCEDURES
Detailed materials and methods can be found in the Supplemental Experimental Procedures.
Cell Line Treatments
Cell lines were treated with 500 nM Aza, 100 nM Dac, or 500 nM-3 mM carboplatin (Sigma) for 72 hr, and DNA and RNA were isolated using standard methods at 1, 3, or 7 days following removal of drug. Ruxolitinib (2 mM) (Invivogen tlrl-rux), 0.625-5 U/ml of anti-IFNAR2 antibody (PBL Interferon Source 21385-1), 0.625-2.5 U/ml of anti-IFNB antibody (PBL Interferon Source 31400-1), or 1.25-5 U/ml of anti-IL10RB antibody (Abcam ab89884) were added during DNMTi treatment. Preparation of nuclear and cytoplasmic fractions of cultured cells was performed as described (O'Hagan et al., 2011) . Ribosomal RNA was depleted using the Ribominus kit (Invitrogen), and PolyA + and PolyA À RNA were isolated using the Oligotex Direct mRNA Mini Kit (Invitrogen). Nucleic acids were treated with 1 U/mg of RNase III (Ambion), 10 U/mg of RNaseH (Invitrogen), or 3 U/1 mg calf intestine alkaline phosphatase (New England Biolabs) according to manufacturer's instructions, and 400 ng of each nucleic acid was transfected into HT29 cells.
DNA Methylation Analysis
DNA was bisulfite converted and subjected to methylation-specific PCR (Herman et al., 1996) for IRF7 and ERV-Fc2 and COBRA (Xiong and Laird, 1997) for the ERV-Fc2 locus on chromosome 11.
Transcript Abundance
Real-time RT-PCR was performed with an Applied Biosystems 7500 Fast Real-Time PCR machine by the 2 ÀDDCT method and TASA-TD strand-specific PCR by the method of Henke et al. (2015) .
Protein Analysis
Western blot analyses employed antibodies against ERV-3 (1:1,000, Everest), B-actin (1:5,000, Sigma), MDA5 Estrogen receptor alpha (ER) , and E-GFP vectors and siRNAs targeting Syncytin-1, ERV-3, or a scrambled control, were transfected using the JetPei or Hyperfect transfection reagents, respectively. TLR3, MAVS, and STING shRNA were performed according to established methods (Stewart et al., 2003) .
Knockdown and Overexpression Experiments
RNA-Seq Expression Analysis of Tumors from Anti-CTLA-4-Treated Patients Patients were described previously (Snyder et al., 2014) and samples were obtained with written informed consent per approved institutional review board (IRB) protocols. Expression data were obtained using RNA-seq with all data deposited at The cBio portal under the study name Metastatic Melanoma (MSKCC Cell, 2015) .
B16-F10 Melanoma Mouse Model
C57BL/6J mice were subcutaneously injected with 1 3 10 5 B16-F10 tumor cells. On days 4, 8, 11, 14, and 18, mice were treated intraperitoneally with 100 mg anti-ctla-4. Mice received two cycles of intraperitoneal injection of 0.1 to 0.75 mg/kg Aza in PBS for 5 consecutive days followed by 7 days off treatment, starting at day 8 after developing palpable tumors, with control groups receiving corresponding doses of non-specific isotype antibody control and PBS intraperitoneally. Tumor surface was measured with a caliper using the ellipse surface formula (length 3 width 3 p)/400. All mouse procedures were performed in accordance with the institutional protocol guidelines from the Memorial Sloan Kettering Cancer Center (New York, NY).
Statistical Analysis
Mean ± SEM qRT-PCR results were considered statistically significant with p values % 0.05 by Mann-Whitney U test or Student's t tests and two-tailed p values are reported. Tumor growth was assessed by two-way ANOVA between each of the mouse treatment groups with p values adjusted by the Dunnett multiple comparison test (df = 512). Normalized, level 3 Agilent expression data were obtained from The Cancer Genome Atlas data portal (https://tcga-data.nci.nih.gov/tcga/) and analyzed by R statistical software (http://www.r-project.org) with existing packages and customized routines. Consensus hierarchical clustering was performed with the ConsensusClusterPlus R-package (Wilkerson and Hayes, 2010) and data analyzed by the Fisher exact p value test for association between clusters.
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